Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
SAN FRANCISCO, Oct. 06, 2016 -- Hagens Berman Sobol Shapiro LLP alerts investors in Alnylam Pharmaceuticals, Inc. that the firm is investigating possible securities law violations by the Company and its officers.
If you purchased or otherwise acquired securities of Alnylam between August 4, 2016 and October 6, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/ALNY
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On October 5, 2016 Alnylam filed its Form 8-K with the SEC publicly announcing it would discontinue testing of one of its key drugs, Revusiran, “upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC).” TheStreet reported on October 6, 2016 that “[w]hen independent monitors peeked into the study results” of Revusiran, they found 18 patients had died, the majority of whom were treated with Revusiran as opposed to placebo. Alnylam has yet to disclose exactly how many of the 18 patients were taking Revusiran during the study.
Alnylam’s disclosures drove its stock price down over 45% during intra-day trading on October 6, 2016.
“We’re looking into when the deaths occurred relative to management’s statements about the drug’s development,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Alnylam should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email. [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
